Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Autoimmune Disease

PUBLISHER: Grand View Research | PRODUCT CODE: 1553471

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1553471

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-steroidal Anti Inflammatory, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Ankylosing Spondylitis Market Growth & Trends:

The global ankylosing spondylitis market size is expected to reach USD 9.12 billion by 2030, registering a CAGR of 6.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province's public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

Ankylosing Spondylitis Market Report Highlights:

  • The TNF (Tumor Necrosis Factor) segment dominated the market and accounted for a revenue share of 59.4% in 2023. TNF inhibitors, which target tumor necrosis factors to manage autoimmune conditions such as rheumatoid arthritis, are anticipated to experience significant growth.
  • The Non-steroidal Anti-Inflammatory Drug (NSAID) market is expected to grow at a CAGR of 8.8% over the forecast years.
  • The North America ankylosing spondylitis market accounted for the largest revenue share of 57.9% in 2023
  • Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share
  • For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China
Show more
Product Code: GVR-4-68038-728-5

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Ankylosing Spondylitis Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Ankylosing Spondylitis Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Ankylosing Spondylitis Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Ankylosing Spondylitis Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
    • 4.3.1. Non-Steroidal Anti-Inflammatory Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. TNF Inhibitors
    • 4.4.1. TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Humira
      • 4.4.2.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Simponi
      • 4.4.3.1. Simponi Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Remicade
      • 4.4.4.1. Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Enbrel
      • 4.4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Cimzia
      • 4.4.6.1. Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.7. Other TNF Inhibitors
      • 4.4.7.1. Other TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Other Drug Classes
    • 4.5.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Ankylosing Spondylitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Ankylosing Spondylitis Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Hospital Pharmacy
    • 5.3.1. Hospital pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Retail Pharmacy
    • 5.4.1. Retail pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis

  • 6.1. Global Ankylosing Spondylitis Market Share, By Region, 2023 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Global Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. AbbiVie, Inc
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Amgen, Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Pfizer, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. UCB, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Novartis AG
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Eli Lilly and Company
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Johnson and Johnson Services, Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck and Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!